| --- | --- | |-----------------------------------------|-------| | | | | | | | | | | | | | Transforming Therapies in Uro-Oncology | | | June 2019 Corporate Presentation | | Forward-Looking Statements 2 This presentation and the accompanying oral presentation by UroGen Pharma Ltd. ("UroGen") contains forward-looking statements. All statements contained herein other than statements of historical fact constitute forward-looking statements, including statements regarding UroGen's anticipated results of operati ...

UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2019 Earnings Conference Call May 9, 2019 8:30 AM ET Company Participants Kate Bechtold - IR Liz Barrett - President and CEO Mark Schoenberg - CMO Peter Pfreundschuh - CFO Conference Call Participants Derek Archila - Stifel Ram Selvaraju - H.C. Wainwright Boris Peaker - Cowen Matt Kaplan - Ladenburg Thalmann Chris Howerton - Jefferies Operator Good morning, ladies and gentlemen. Thank you for standing by and welcome to UroGen Pharma's First Quarter 2019 Financial Results ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Exact Name of Registrant as Specified in its Charter) WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____________ to ________________ Commission file number: 001-38079 UROGEN PHARMA LTD. Israel 98-1460746 ( ...

| --- | --- | |-------------------------------------------------------------------------|-------| | | | | | | | | | | | | | | | | Transforming Local Therapies in Uro-Oncology | | | March 12, 2019 Cowen and Company 39 th Annual Health Care Conference | | Forward-Looking Statements 2 This presentation and the accompanying oral presentation by UroGen Pharma Ltd. ("UroGen") contains forward-looking statements. All statements contained herein other than statements of historical fact constitute forward-looking st ...

UroGen Pharma (NASDAQ:URGN) Q4 2018 Earnings Conference Call February 28, 2019 8:30 AM ET Company Participants Kate Bechtold - Director, Corporate Communications and Investor Relations Liz Barrett - President and Chief Executive Officer Mark Schoenberg - Chief Medical Officer Peter Pfreundschuh - Chief Financial Officer Conference Call Participants Ram Selvaraju - H. C. Wainwright Boris Peaker - Cowen Leland Gershell - Oppenheimer Chris Howerton - Jefferies Operator Good morning, ladies and gentlemen. Thank ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Exact name of registrant as specified in its charter) Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____________ to ________________ Commission file number: 001-38079 UROGEN PHARMA LTD. Indicate by check mark ...